Inhibikase Therapeutics Inc Share Price

NASDAQ: IKT

Small Cap

$1.59

+0.03

(+2.24%)

as on September 16, 2025 at 1:29 am IST

$₹

Inhibikase Therapeutics Inc Stock Performance

as on September 16, 2025 at 1:29 am IST

Day's Low
Day's High
$1.5
Day's Price Range
$1.6
$1.59
5.66%
Downside
0.63%
Upside
52 Week's Low
52 Week's High
$1.12
52-Week Price Range
$4.2
$1.59
29.56%
Downside
164.15%
Upside

Inhibikase Therapeutics Inc share price movements today

Previous Close: $1.56
Open: $1.55
Volume: 859.0K
Day's Low - High: $1.5 - $1.6
52 Week Low - High: $1.12 - $4.2

Inhibikase Therapeutics Inc Historical Returns

1 Month Return: -10.86 %
3 Month Return: -16.13 %
1 Year Return: + 32.2 %
3 Year Return: -76.58 %
5 Year Return: 0 %

Inhibikase Therapeutics Inc Stock Fundamentals & Key Indicators

Check Inhibikase Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$116.2M

EPS (TTM)

-0.51

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.56

Industry PE ratio

P/B Ratio

PEG Ratio

EBITDA

-44.1M

Revenue (TTM)

1.0

Profit Margin

0.00%

Return On Equity TTM

580000.00%

Inhibikase Therapeutics Inc Stock Valuation

Track how Inhibikase Therapeutics Inc P/E has moved over time to understand its valuation trends.

Inhibikase Therapeutics Inc in the last 5 years

Overview
Trends

Lowest (0.00x)

September 15, 2025

Industry (0.00x)

September 15, 2025

Today (-0.56x)

September 15, 2025

Highest (-0.37x)

December 31, 2023

LowHigh

Today’s Price to Earnings Ratio: -0.56x

Inhibikase Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Inhibikase Therapeutics Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Inhibikase Therapeutics Inc	BUY	$116.2M	NA	-0.56	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$61.1B	256.98%	-505.15	-12.96%
Beone Medicines Ltd	NA	$38.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$101.1B	47.85%	28.07	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$59.4B	-3.43%	14.11	31.37%

Stock Returns calculator for Inhibikase Therapeutics Inc Stock including INR - Dollar returns

The Inhibikase Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Inhibikase Therapeutics Inc investment value today

Current value as on today

₹1,39,731

Returns

₹39,731

(+39.73%)

Returns from Inhibikase Therapeutics Inc Stock

₹34,746 (+34.75%)

Dollar Returns*

₹4,985 (+4.99%)

Analyst Recommendation on Inhibikase Therapeutics Inc Stock

Based on 6 analysts

BUY

83.33%

Buy

16.67%

Hold

0.00%

Sell

Based on 6 analysts, 83.33% of analysts recommend a 'BUY' rating for Inhibikase Therapeutics Inc. Average target price of $8

Inhibikase Therapeutics Inc Share Price Target

Get share price movements and forecasts by analysts on Inhibikase Therapeutics Inc.

What analysts predicted

80.13%UPSIDE

Target Price

Current Price

$1.59

Analyzed by

6 Analysts

Target

$8.00

Inhibikase Therapeutics Inc target price $8, a slight upside of 80.13% compared to current price of $1.59. According to 6 analysts rating.

Inhibikase Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	0	0	0	0	-	-	-	0	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-4	-6	-4	-4	-4	-5	-5	-12	-14	-10
EBITDA	-4	-6	-4	-4	-4	-5	-5	-12	-15	-11
Interest Expense	0	0	0	0	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-4	-5	-4	-4	-4	-4	-5	-12	-13	-9
Income Tax Expense	0	0	0	0	0	0	-	-	-	-
Net Income	-4	-5	-4	-4	-4	-4	-5	-12	-13	-9
Net Profit Margin	-6204.86%	-4963.46%	-5775.11%	-417794000.00%	0.00%	0.00%	0.00%	-46177.12%	0.00%	0.00%

Inhibikase Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	0	2	4	1	0	3	0	0	-
Gross Profit	0	0	4	-1	0	3	0	-13	0
Operating Income	0	0	-2	-5	-2	-14	-18	-20	-28
EBITDA	-	-	-2	-5	-2	-14	-18	-19	-27
Interest Expense	-	-	0	0	0	0	0	0	-
Depreciation	-	-	-	-	-	-	0	0	0
Income Before Tax	0	0	-2	-5	-2	-14	-18	-19	-27
Income Tax Expense	0	0	0	0	0	0	0	0	-
Net Income	0	0	-2	-5	-2	-14	-17	-19	-27
Net Profit Margin	-64.99%	-21.16%	-53.27%	-511.95%	-411.94%	-477.52%	-14505.22%	-7304.75%	0.00%

Inhibikase Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-5	-4	-4	-4	-4	-5	-12	-13	-9
Operating Cash Flow	-4	-4	-3	-3	-5	-4	-5	-4	-5
Investing Cash Flow	2	17	-2	-3	2	2	-38	21	9
Financing Cash Flow	0	0	0	0	3	0	99	-	0
Change in Cash	-2	12	-5	-6	0	-2	55	16	4

Inhibikase Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-2	-5	-2	-14	-18	-19	-27
Operating Cash Flow	0	0	-1	-14	-17	-18	-19
Investing Cash Flow	0	-	-	-	-	11	-37
Financing Cash Flow	0	0	15	41	0	8	103
Change in Cash	0	0	13	26	-33	1	47

Global Institutional Holdings in Inhibikase Therapeutics Inc

Funds	Holdings
Sands Capital Ventures, LLC	14.73%
Soleus Capital Management, L.P.	8.51%
Fairmount Funds Management LLC	8.24%
Perceptive Advisors LLC	7.97%
COMMODORE CAPITAL LP	7.19%

See all

Insights on Inhibikase Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -13.67M → -9.91M (in $), with an average increase of 38.0% per quarter
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 1.0 → 26.27K (in $), with an average increase of 100.0% per quarter
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 72.3% return, outperforming this stock by 37.8%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 118.7% return, outperforming this stock by 193.2%
NEGATIVE IMPACT
Price Dip
In the last 7 days, IKT stock has moved down by -6.6%

About Inhibikase Therapeutics Inc

inhibikase therapeutics, inc., a clinical stage pharmaceutical company, develops therapeutics for parkinson's disease, and related disorders that arise inside and outside of the brain. the company's product candidates include ikt-148009, a c-abl protein kinase inhibitor for use in the treatment of parkinson's disease, dysphagia, and neurogenic constipation; and ikt-001pro, a prodrug of the anti-cancer agent imatinib that is in preclinical development to minimize gastrointestinal side effects. it offers products comprise ikt-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body; and ikt-148x series of portfolio compounds for use in the treatment of dementia with lewy body and multiple system atrophy. the company was founded in 2008 and is headquartered in atlanta, georgia.

Organisation	Inhibikase Therapeutics Inc
Headquarters	3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339
Industry	Health Technology
CEO	Mr. Mark T. Iwicki
E-voting on shares	Click here to vote

Key Management of Inhibikase Therapeutics Inc

Name	Title
Mr. Mark T. Iwicki	CEO & Director
Dr. Christopher H. Cabell FACC, M.D.	President, Head of Research & Development and Chief Medical Officer
Mr. David John McIntyre B.Econs(Acc), BEC, C.P.A., L.L.B., M.B.A.	Chief Financial Officer
Dr. John Adams Ph.D.	Chief Scientific Officer
Mr. Jeffrey J. Kagy	Chief Human Resources Officer
Mr. Chadwick J. Orevillo MPH	Executive VP & Head of Development Operations
Mr. Timothy J. Pigot	Chief Commercial & Strategy Officer

FAQs

What is Inhibikase Therapeutics Inc share price today?

Inhibikase Therapeutics Inc share price today is $1.59 as on September 16, 2025 at 1:29 am IST at the close of the market. Inhibikase Therapeutics Inc share today touched a day high of $1.6 and a low of $1.5.

What is the 52 week high and 52 week low for Inhibikase Therapeutics Inc share?

Inhibikase Therapeutics Inc share touched a 52 week high of $4.2 on December 18, 2024 and a 52 week low of $1.12 on September 25, 2024. Inhibikase Therapeutics Inc stock price today i.e. September 16, 2025 at 1:29 am IST is closed at $1.59,which is 62.14% down from its 52 week high and 41.96% up from its 52 week low.

What is Inhibikase Therapeutics Inc's market capitalisation today?

Inhibikase Therapeutics Inc market capitalisation is $0.00T as on September 16, 2025 at 1:29 am IST.

How to invest in Inhibikase Therapeutics Inc Stock (IKT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Inhibikase Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Inhibikase Therapeutics Inc Shares that will get you 0.9434 shares as per Inhibikase Therapeutics Inc share price of $1.59 per share as on September 16, 2025 at 1:29 am IST.

What is the minimum amount required to buy Inhibikase Therapeutics Inc Stock (IKT) from India?

Indian investors can start investing in Inhibikase Therapeutics Inc (IKT) shares with as little as ₹88.141 or $1 (as of September 16, 2025 at 7:42 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹881.41 in Inhibikase Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on September 16, 2025 at 7:42 am IST). Based on Inhibikase Therapeutics Inc share’s latest price of $1.59 as on September 16, 2025 at 1:29 am IST, you will get 6.2893 shares of Inhibikase Therapeutics Inc. Learn more about fractional shares .